Table 4 Association between polymorphisms in the genes of TS, ERCC1, XPD, XPA, XRCC1, GSTP1, GSTT1, and GSTM1 and survival and progression after 5-FU/oxaliplatin chemotherapy

From: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  

Survival

Progressiona

Factors

No. of patients

Relative risk of dyingb and 95% CI

P-valuec

Relative risk of progressiona and 95% CI

P-valuec

XPD-751

  

0.049

 

0.76

 Lys/Lys

40

1

 

1

 

 Lys/Gln

53

1.87 (1.06, 3.31)

 

1.13 (0.72, 1.78)

 

 Gln/Gln

13

2.44 (1.09, 5.44)

 

1.25 (0.59, 2.67)

 

XPD-156

  

0.88

 

0.64

 A/A

14

1

 

1

 

 C/A

59

1.22 (0.55, 2.75)

 

0.81 (0.44, 1.49)

 

 C/C

30

1.18 (0.49, 2.82)

 

0.73 (0.36, 1.48)

 

 Unknown

3

    

XPA-5′

  

0.76

 

0.61

 G/G

24

1

 

1

 

 A/G

53

0.88 (0.47, 1.62)

 

1.24 (0.70, 2.18)

 

 A/A

16

1.13 (0.49, 2.45)

 

1.37 (0.66, 2.84)

 

 Unknown

13

    

ERCC1-118

  

0.021

 

0.51

 C/C

30

1

 

1

 

 C/T

45

2.29 (1.19, 4.41)

 

1.24 (0.73, 2.11)

 

 T/T

31

1.86 (0.91, 3.83)

 

1.36 (0.76, 2.41)

 

XRCC1-399

  

0.50

 

0.97

 Arg/Arg

44

1

 

1

 

 Gln/Arg

51

1.07 (0.63, 1.80)

 

0.95 (0.60, 1.51)

 

 Gln/Gln

10

1.58 (0.71, 3.55)

 

0.99 (0.47, 2.09)

 

 Unknown

1

    

TS-3′UTR

  

0.72

 

0.22

 +6BP/+6BP

37

1

 

1

 

 +6BP/−6BP

52

1.23 (0.70, 2.15)

 

1.49 (0.92, 2.40)

 

 -6BP/−6BP

13

1.18 (0.52, 2.66)

 

1.39 (0.70, 2.75)

 

 Unknown

4

    

TS-5′UTR

  

0.42

 

0.44

 3R/3R

43

1

 

1

 

 2R/3R

46

0.82 (0.49, 1.39)

 

0.78 (0.48, 1.26)

 

 2R/2R

16

1.32 (0.64, 2.75)

 

1.06 (0.55, 2.02)

 

 2/4

1

    

GSTP1-105

  

0.019

 

0.011

 Val/Val

10

1

 

1

 

 Ile/Val

47

1.82 (0.71, 4.66)

 

1.22 (0.56, 2.67)

 

 Ile/Ile

49

2.96 (1.15, 7.61)

 

2.13 (0.95, 4.76)

 

GSTT1

  

0.29

 

0.93

 Positive

75

1

 

1

 

 Negative

27

1.33 (0.78, 2.28)

 

0.98 (0.60, 1.60)

 

 Unknown

4

    

GSTM1

  

0.59

 

0.58

 Positive

54

1

 

1

 

 Negative

48

1.14 (0.69, 1.88)

 

1.13 (0.72, 1.76)

 

 Unknown

4

    
  1. 5-FU=5-fluorouracil; CI=confidence interval; GSTP=glutathione S-transferase; TS=thymidylate synthase; UTR=untranslated region.
  2. aTime to progression was calculated from the time that patient started treatment until the patient was taken off study. If the relative risk is greater than 1, the relative risk can be thought as the average increased risk of progression at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
  3. bIf the relative risk is greater than 1, the relative risk can be thought as the average increased risk of dying at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
  4. cP-value based on log-rank test.
Back to article page